AllDocs -> heart diseases

This educational brochure has been provided by Pharmion Corporation in partnership with your healthcare provider. For more information, you may find the following resources helpful: American Cancer Society 1-800-ACS-2345 www.cancer.org National Cancer Institute 1-800-4-CANCER (1-800-422-6237) www.nci.nih.gov American Heart Association 1-800-AHA-USA-1 (1-800-242-8721) www.americanheart. org National Heart, Lung, and Blood Institute www.nhlbi.nih.gov American Geriatrics Society www.americangeriatrics.org www.pharmion.com References: 1. DeSancho MT, Rand JH. Bleeding and thrombotic complications in critically ill patients with cancer. Crit Care Clin . 2001;17(3):599-622. 2. Anand SS, Wells PS, Hunt D, et al. Does this patient have deep vein thrombosis ? JAMA . 1998;279(14):1094-1099. 3. Dellinger RP. Is your patient at risk for venous ...

1 Case: 35 yo man c ESRD on HD with a L-sided AV fistula that had recently been manipulated comes to ER with diffusely swollen LUE. What is your differential dx, how would you evaluate and treat this patient? Deep Venous Thrombosis Erin Sutcliffe, M.D. Harborview Medical Center Risk factors (remember Virchow’s Triad – stasis, hypercoagulability, endothelial injury) 1) OCP, pregnancy/post-partum, HRT 2) Smoking 3) Malignancies 4) Vasculitidies 5) Hypercoaguable states 6) Surgery 7) Trauma 8) Immobilization, obesity 9) Hyperviscosity 10) Nephrotic syndrome 11) CHF 12) ETC. Diagnosis – see diagnosis algorithm at end of worksheet (Table 1) 1) U/S aka Doppler – preferred first line test Serial Dopplers (5-7 days) recommended in suspected distal DVT with negative initial Doppler with high ...

Medical Progress 1222 · N Engl J Med, Vol. 344, No. 16 · April 19, 2001 · www.nejm.org The New England Journal of Medicine G ENETIC S USCEPTIBILITY TO V ENOUS T HROMBOSIS U RI S ELIGSOHN , M.D., AND A HARON L UBETSKY , M.D. From the Institute of Thrombosis and Hemostasis and the National He- mophilia Center, Department of Hematology, Chaim Sheba Medical Cen- ter, Tel Hashomer, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv — both in Israel. Address reprint requests to Dr. Seligsohn at the In- stitute of Thrombosis and Hemostasis, Chaim Sheba Medical Center, Tel Hashomer 52621, Israel, or at zeligson@post.tau.ac.il. HE annual incidence of venous thrombosis , one of the leading causes of mortality ...

How I treat How we diagnose and treat deep vein thrombosis Jack Hirsh and Agnes Y. Y. Lee Making a diagnosis of deep vein thrombo- sis (DVT) requires both clinical assess- ment and objective testing because the clinical features are nonspecific and in- vestigations can be either falsely positive or negative. The initial step in the diagnos- tic process is to stratify patients into high-, intermediate-, or low-risk catego- ries using a validated clinical model. When the clinical probability is intermediate or high and the venous ultrasound result is positive, acute symptomatic DVT is con- firmed. Similarly, when the probability is low and the ultrasound result is normal, DVT is ruled out. A low clinical probability combined with a negative D-dimer result can also be used to rule out DVT, thereby obviating the need for ultrasonography. ...

Turk J Med Sci 2006; 36 (4): 247-250 © TÜB‹TAK E-mail: medsci@tubitak.gov.tr 247 CASE REPORT Arterial Thrombosis in Refractory Multiple Myeloma Patient Treated with Thalidomide and Dexamethasone: A Case Report Abstract: A 48-year-old man with relapsing multiple myeloma (MM) presented with serum monoclonal protein (IgG ? ) of 5.93 g/dl. He was initially treated with four cycles of VAD (vincristine, adriamycin and dexamethasone) but due to deterioration of his renal functions with disease relapse, he was placed on hemodialysis. A combined treatment with thalidomide at a daily dose of 200 mg and 4-d cycles of dexamethasone was started for relapsing MM. Thalidomide dose was increased to 400 mg after two weeks. In the second month of his treatment, the patient presented with progressive drowsiness without other symptoms. His cranial MR was suggestive of arterial thrombosis . ...

THROMBOSIS AND THROMBOEMBOLISM: NEW STRATEGIES FOR IMPROVED PATIENT CARE OCTOBER 12-13, 2006 Presented by CARDIOVASCULAR DIVISION, BRIGHAM AND WOMEN’S HOSPITAL at the Fairmont Copley Plaza Hotel - Boston, Massachusetts Course Directors Samuel Z. Goldhaber, M.D. and Paul M Ridker, M.D. www.cme.hms.harvard.edu/courses/ thrombosis The objective of this two-day course is for internationally recognized faculty to provide a concise, state-of-the-art overview of critical developments in the diagnosis, treatment, and prevention of thromboembolic disorders in the coronary, carotid, pulmonary, peripheral arterial, and venous systems. The course, offered once every 3 years, is intended for all general internists and cardiovascular, peripheral vascular, critical care, pulmonary, surgical, and hematologic specialists who are called upon to care for patients ...

Press Release CONTACT: Hampton Shaddock 202.530.4766 Coalition to Prevent Deep-Vein Thrombosis (DVT) Applauds the National Comprehensive Cancer Network’s New Guidelines for DVT NCCN DVT Guidelines for cancer patients may help to reduce the risk of this serious medical condition Washington, D.C., May 19, 2006 – The Coalition to Prevent Deep-Vein Thrombosis (DVT) today announced its support of the National Comprehensive Cancer Network’s (NCCN) new guidelines which address how to reduce the risk of DVT in cancer patients and how to treat a DVT if one develops. “With cancer patients proven to be at greater risk for DVT, these new guidelines may provide physicians with tools to assess patients’ risk,” said Coalition member Larry Wellikson, MD, FACP, Chief Executive Officer, Society of Hospital Medicine. According to the American Heart Association, up to 2 million ...

Correspondence: Dr Mithun Raj Department of Medicine Jawaharlal Institute of Postgraduate Medical Education and Research; Pondicherry; 605006; India E mail: drmithunraj@gmail.com BREAST TUMOUR PRESENTING AS RECURRENT DEEP VEIN THROMBOSIS Mithun Raj, Padhan Prasantha, Ramakrishnan Santhosh, Sethuraman KR Jawaharlal Institute of Postgraduate Medical Education and Research, Internal Medicine, Pondicherry, India Deep vein thrombosis development during the course of treatment of breast carcinoma has been well described, but carcinoma breast presenting with DVT for the first time is highly unusual. We present the case of a 45 year old women with recurrent deep vein thrombosis of left lower limb. During the second episode she was found to have infiltrating ductal carcinoma of the right breast with axillary lymph node metastasis. To our knowledge ...

19 th International Congress on Thrombosis May 14 – 18, 2006 Tel-Aviv, Israel Main Topics: • Antiphospholipid Syndrome • Antithrombotic Drugs - The Old and the New • Arterial Atherothrombosis • Atherothrombosis • Cancer and Thrombosis • Critical Limb Ischaemia • D-Dimer and Thrombotic Risk • Diagnosis of Venous Thromboembolism • Disseminated Intravascular Coagulation • Epidemiology of Thrombosis • Fibrinolysis and Thrombosis • Gene Therapy • Heparin Induced Thrombocytopenia • Homocysteine • Inflammation and Thrombosis • Lupus Anticoagulants and Antiphospholipid Antibodies • Nutrition and Antioxidants • Oral Anticoagulants • Peripheral Arterial Disease • Platelets and Thrombosis • Polymorphisms in Haemostatic Proteins and Thrombosis • Prophylaxis ...

Increased Thrombosis After Arterial Injury in Human C-Reactive Protein–Transgenic Mice Haim D. Danenberg, MD; Alexander J. Szalai, PhD; Rajesh V. Swaminathan, BSc; Lin Peng, MD; Zhiping Chen, MS; Philip Seifert, MS; William P. Fay, MD; Daniel I. Simon, MD; Elazer R. Edelman, MD, PhD Background —C-reactive protein (CRP), an acute-phase reactant long considered merely an innocent bystander in the inflammatory process, is now recognized as a powerful predictor of cardiovascular events. Emerging in vitro evidence suggests that CRP may have direct proinflammatory and prothrombotic effects on monocytes and endothelial cells. To determine whether CRP directly modulates vascular cell function in vivo, we subjected wild-type mice, which do not express CRP, and human CRP–transgenic (CRPtg) mice to 2 models of arterial injury. Methods and Results —Baseline serum CRP levels in CRPtg mice were 18 6 mg/L. CRP levels were ...

n engl j med 352;17 www.nejm.org april 28, 2005 The new england journal of medicine 1791 review article current concepts Thrombosis of the Cerebral Veins and Sinuses Jan Stam, M.D., Ph.D. From the Department of Neurology, Aca- demic Medical Center, University of Am- sterdam, Amsterdam. Address reprint re- quests to Dr. Stam at the Department of Neurology, Academic Medical Center, Uni- versity of Amsterdam, P.O. Box 22700, 1100 DE Amsterdam, the Netherlands, or at j.stam@amc.uva.nl. N Engl J Med 2005;352:1791-8. Copyright © 2005 Massachusetts Medical Society. hrombosis of the cerebral veins and sinuses is a distinct cere- brovascular disorder that, unlike arterial stroke, most often affects young adults and children. The symptoms and clinical course are highly variable. A teenag- er who has had recent headaches ...

thrombosis 1581 Cerebral Vein & Sinus Thrombosis Dr Anna Kalff Clinical Haematology Registrar Cerebral Vein Thrombosis < 2% of all strokes Predominantly affects young adults and children Male: uniform age distribution Females: 61% CVT in 20-35 age group 75% of adult patients are women (ISCVT study) Accounts for up to 50% of strokes during pregnancy and puerperium Incidence 3-4 per 1 million population Pathogenesis 1. Thrombosis of cerebral veins - Local effects caused by venous obstruction, oedema of brain (both cytotoxic and vasogenic) and infarction due to elevated venous and capillary pressure - complicated by haemorrhage – may be multiple and bilateral, and not respect arterial vascular ...

Contact: Julia Jackson 212.614.4995 COALITION TO PREVENT DEEP-VEIN THROMBOSIS (DVT) SUPPORTS NQF SUMMIT AS A VITAL STEP TO ADVANCE CARE AND TREATMENT OF DVT -—Conference lays groundwork to address a serious medical condition— WASHINGTON, D.C., March 24, 2006 – Today, the National Quality Forum (NQF) convenes a summit with leaders in the healthcare community to develop a strategy to advance the risk reduction and treatment of DVT. Each year, approximately two million Americans are affected by DVT and its complication, pulmonary embolism, (PE), which causes up to 200,000 deaths annually. The Coalition to Prevent DVT supports NQF’s Summit’s as an important step in laying a nation-wide foundation to reduce the incidence of this potentially silent killer. “The Coalition’s hope is that this Summit will draw attention to DVT among the highest levels of healthcare professionals. We believe ...

Patient Information Addenbrooke’s Hospital Risk of venous thrombosis and long distance travel 1 of 2 Thrombosis Treatment Team Risk of venous thrombosis and long distance travel (including air flights) - Information for travellers Background There has recently been considerable media interest in the risk of blood clots triggered by air flights. A study from North America indicated that the risk of a fatal blood clot after a trans- Atlantic air flight is less than one in a million. • • • • • • • • • • • • • • Additional studies indicate that the greatest risk of a blood clot is when there are additional risk factors, such as an operation in the previous few weeks. The risk is related to the duration of travel, with the lowest risk for journeys that are less than six hours. ...

Patient Information About the Thrombosis Treatment Team Page 1 of 2 Emergency Assessment Unit About the Thrombosis Treatment Team The Thrombosis Treatment Team is a nurse led service specialising in the assessment of Deep Vein Thrombosis (DVT) and outpatient treatment of DVT and pulmonary embolism (PE). There are four nurse specialists in the team: Annie Davenport Caroline Lewis Ann Taylor Mary Howard Information for patients diagnosed with deep vein thrombosis (DVT) DVT is the formation of a blood clot in a deep vein, most commonly in the leg but it can also occur in the arm. After diagnosis, you will be taken to the Emergency Assessment Unit where you will be examined by a doctor. This may include further blood tests, chest x-ray and any other investigations the doctor considers necessary. You will need to wait for the results of these ...

R:\DOC\PRINTED\MISCELL\P702-WHI Update DVT Update.doc 09/01/97 WHI Update September 1, 1997 WHAT YOU SHOULD KNOW ABOUT DEEP VEIN THROMBOSIS (DVT) Participants in the Hormone Program of the Women’s Health Initiative will be helping us to get answers to questions about heart disease, cancer, and fractures. We have developed this fact sheet to give you some information about deep vein thrombosis or blood clots. A small number of women (and men, for that matter) can develop these types of blood clots in the veins of their legs or lungs. A few recently published studies have reported that hormone replacement therapy (HRT) may increase this risk a little, but the risk is still very low. We hope this information helps you to reduce your risk of developing deep vein thrombosis . What is DVT? Deep vein thrombosis or DVT is not common. It occurs when a blood clot ...

Thrombosis Risk Factor Assessment / Guidelines Choose All That Apply Each Risk Factor Represents 1 Point ”Each” Each Risk Factor Represents 2 Points ”Each” Minor Surgery Planned Patient is 61-74 years old Patient is 41-60 years old Malignancy-except skin (present or previous) History of prior major surgery (<1 month) Major Surgery (>45 minutes) Varicose Veins Laparoscopic surgery (>45 minutes) Inflammatory Bowel Disease Patient confined to bed (>72 hours) pre & post admission Swollen legs (current) Lower extremity immobilizing cast (<1 month) Obesity Central venous access (<1 month) Oral contraceptives or hormone replacement therapy Each Risk Factor Represents 3 Points ”Each” Each Risk Factor Represents 5 Points ”Each” History of DVT/PE Elective total hip or knee replacement Family history of thrombosis ...

DISORDER/SETTING Question 1: What is the specific clinical disorder to be studied? Question 2: What are the clinical findings defining this disorder? Question 3: What is the clinical setting in which the test is to be performed? Question 4: Question 5: Question 6: )? What DNA test(s) are associated with this disorder? Are preliminary screening questions employed? Is it a stand-alone test or is it one of a series of tests? Question 7: If it is part of a series of screening tests, are all tests performed in all instances (parallel) or are only some tests performed on the basis of other results (series VTE -- Version 2004 - 3 Disorder/Setting 1-1 Page 2 DISORDER/SETTING Question 1: What is the specific clinical disorder to be studied? adults with an inherited clotting disorder. The disorder being considered in this review ...

CLINICAL UTILITY Question 26: What is the natural history of the disorder? Question 27: What is the impact of a positive (or negative) test on patient care? Question 28: If applicable, are diagnostic tests available? Question 29: Is there an effective remedy or acceptable action, or other measurable benefit? Question 30: Is there general access to that remedy or action? Question 31: Is the test being offered to a socially vulnerable population? Question 32: What quality assurance measures are in place? CLINICAL UTILITY Summary • causes. • • percent. • Question 33: What are the results of pilot trials? Question 34: What health risks can be identified for follow-up testing and/or intervention. Question 35: What are the financial costs associated with testing? Question 36: What are the economic benefits associated with actions resulting from testing? Question ...

198 Volume 41 • Number 2 • June 2006 Journal of Athletic Training 2006;41(2):198–200 by the National Athletic Trainers’ Association, Inc www.journalofathletictraining.org Atraumatic Subclavian Vein Thrombosis in a Collegiate Baseball Player: A Case Report Wendy L. Hurley*; Sonya A. Comins*; Richard M. Green†; John Canizzaro‡ * State University of New York College at Cortland, Cortland, NY; †Lenox Hill Hospital, New York, NY; ‡State University of New York Upstate Medical University, Syracuse, NY Wendy L. Hurley, PhD, ATC, CSCS, contributed to conception and design; analysis and interpretation of the data; and drafting, critical revision, and final approval of the article. Sonya A. Comins, MSEd, ATC, contributed to conception and design; acquisition and analysis and interpretation of the data; and drafting, critical revision, and final approval ...

CLINICAL VALIDITY Question 18: How often is the test positive when the disorder is present (i.e. sensitivity)? Question 19: How often is the test negative when the disorder is not present (i.e. specificity)? Question 20: Are there methods to resolve clinical false positive results in a timely manner? Question 21: What is the prevalence of the disorder in this setting? Question 22: Has the test been adequately validated on all populations to which it may be offered? Question 23: What are the positive and negative predictive values? Question 24: What are the genotype/phenotype relationships? Question 25: What are the genetic, environmental or other modifiers? CLINICAL VALIDITY Question 18: How often is the test positive when the disorder is present (i.e. sensitivity)? Question 19: How often is the test negative when the disorder is not present (i.e. specificity)? Summary Disorder/Setting ...

Inferior vena cava thrombosis 1 Inferior Vena Cava Thrombosis Brian Kilpatrick South Piedmont Community College Sonography 130 M. Alice Bradley, RTR, RDMS Page 2 Inferior vena cava thrombosis 2 Abstract The inferior vena cava is the largest vein in the vascular system. It is responsible for carrying deoxygenated blood from the distal parts of the body to the right atrium for oxygenation. The most common pathology in the inferior vena cava is thrombosis . In the late 1800’s Trousseau proposed the idea of placing a barrier in the inferior vena cava to prevent pulmonary embolus. Aside from thrombolytic therapy, the current treatment for thrombosis is the placement of inferior vena cava filters, of which there are several types. All have around the same efficacy rate. Page 3 Inferior vena cava thrombosis ...

Please visit us online at: http://aha.medcareers.com Or visit ATVB online at: http://atvb.ahajournals.org/ F OR I NFORMATION AND A D P LACEMENT C ONTACT : J ENNIFER W ILLIAMS A RTERIOSCLEROSIS , T HROMBOSIS , AND V ASCULAR B IOLOGY L IPPINCOTT W ILLIAMS & W ILKINS 351 W EST C AMDEN S TREET B ALTIMORE , MD 21201-2436 T ELEPHONE : 1-800-528-1843 OR 410-528-4049 F AX : 410-528-4452 E- MAIL : jennifer.m.williams@wolterskluwer.com B ...

1 Thrombosis In Pregnancy: The Role of Factor V Leiden, Prothrombin 20210 G to A, Angiotensin Converting Enzyme and Methylenetetrahydrofolate Reductase in a U.S. Population Anne Dilley Ph.D. 1 , Harland Austin D.Sc. 1,2 , Muhydine El-Jamil M.P.H. 1,2 , W. Craig Hooper Ph.D. 1 , Elizabeth Barnhart M.P.H. 1 , Bruce L. Evatt M.D. 1 , Patrick S. Sullivan Ph.D. 1 , Dorothy Ellingsen 1 , Anne Patterson-Barnett M.D. 3 , Daniel Eller M.D. 3 , Hugh Randall M.D. 4 , Claire Philipp M.D. 5 1 Division of AIDS, STD, and Laboratory Research, National Center for Infectious Diseases, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, Atlanta, Georgia 2 Department of ...

XIIIth Paavo Nurmi Symposium 1-3.9.2000 Hanasaari Espoo F INAL ANN OU NCE ME N T ”Arterial Thrombosis – from Mechanisms to Treatment” Lectures: All Lectures are 30 min + 5 min discussion. Candlelight Lecture is 45 min. Proceedings of the XIIIth Paavo Nurmi Symposium Annals of Medicine All the speakers are asked to provide upon arrival a minireview type of article of their topic with 10 double-spaced pages including references (max. 30). Tables and illustrative material are most welcome. Even sketches can be submitted to be prepared by a highly qualified profes- sional and forwarded to you for approval. The proceedings will be published in Annals of Medi- cine, an official journal of the Finnish Medical Society, Duodecim. Social Program A get-together party will be organised at Hanasaari on Friday evening, the 1st of September ...

© The Ulster Medical Society, 2006. 88 The Ulster Medical Journal www.ums.ac.uk Ulster Med J 2005; 75 (1) 88-90 IntroductIon Heparin-induced thrombocytopenia with thrombosis (HITT) is a rare but potentially fatal autoimmune syndrome, which is caused by antibody formation against complexes of heparin and platelet factor 4 (PF4). It typically develops five to fourteen days after the initiation of unfractionated or much less frequently low molecular weight heparin. The mortality rate can reach 20-30% and is associated mainly with thrombosis . Thrombotic events are most frequently venous but arterial thrombosis leading to myocardial infarction and ischemic limb damage requiring amputation also occur. 1 No consensus currently exists on the best alternative anticoagulant treatment, especially in cases with renal ...

Deep Vein Thrombosis (DVT) What is a deep vein thrombosis ? A deep vein thrombosis (DVT) is a blood clot that forms in a deep leg vein. Veins are blood vessels that take blood towards the heart. Deep leg veins are the larger veins that go through the muscles of the calf and thighs. (They are not the veins that you can see just below the skin.) When you have a DVT the blood flow in the vein is partially or completely blocked, depending on whether the blood clot partially or completely fills the width of the vein. A calf vein is the common site for a DVT. A thigh vein is less commonly affected. Rarely, other deep veins in the body form blood clots. Why do blood clots form in leg veins? Blood normally flows quickly through veins, and does not usually clot. Sometimes a DVT occurs for no apparent reason. However, the following increase the risk of having a DVT. ...

December/January 2006 Thrombosis Express/ L’Express Thrombose “Practice changing knowledge generation, developing tomorrow’s leaders and delivering quality cost effective care.” Dec./Jan. 2006 Publications Impact Factor Points: Last year’s total 68.7 (April ’04 - March ’05), so far this year 63.4 (April ’05 - Present). Almost at last year’s total in 10 months! Wells PS, Owens C, Doucette S, Fergusson D, Tran H. Does this patient have deep vein thrombosis ? JAMA January 2006;295:199-207. Crowther MA, Cook DJ, Griffith LE, Devereaux PJ, Rabbat CC, Clarke FJ, Hoad N, McDonald E, Meade MO, Guyatt GH, Geerts WH, Wells PS. Deep venous thrombosis : clinically silent in the intensive care unit. J Crit Care. 2005 Dec;20(4):334-40. Kovacs MJ, Kovacs J, Anderson J, Rodger MA, K MacKinnon, Wells PS. Protein C and protein S levels can be accurately determined within 24 hours of diagnosis ...

1 October/November 2005 Thrombosis Express/ L’Express Thrombose “Practice changing knowledge generation, developing tomorrow’s leaders and delivering quality cost effective care.” Oct./Nov. 2005 Publications Impact Factor Points: Last year’s total 68.7 (April ’04 - March ’05), so far this year 36.74 (April ’05 - Present). Wells PS. The role of qualitative D-dimer assays, clinical probability and non- invasive imaging tests for the diagnosis of deep vein thrombosis and pulmonary embolism. Seminars in Vascular Medicine 2005; 5 (4):340-350. (November 2005 issue) Anderson DR, Kovacs MJ, Dennie C, Kovacs G, Stiell I, Dreyer J, McCarron B, Pleasance S, Burton E, Cartier Y, Wells PS . Use of spiral computed tomography contrast angiography and ultrasonography to exclude the diagnosis of pulmonary embolism in the emergency department. J Emerg Med 2005;29 (4):399-404. ...

Thursday, May 4 and Friday, May 5, 2006 Westin Hotel, Downtown Indianapolis, IN Announcing the Eighth Annual Symposium on Bleeding & Thrombosis Presented by Hemostasis and Thrombosis Laboratories Page 2 Symposium Overview The Eighth Annual Symposium on Bleeding & Thrombosis has been enhanced to provide new educational opportunities for professionals of all levels. It features two sessions: Applied Hemostatis & Thrombosis (Track 1) and Fundamentals of Coagulation Testing (Coag 101). Additionally, this year’s program allows participants to choose a mix of Track 1 and Coag 101 sessions. The Symposium is a convenient and affordable way to: • Advance your practical skills and knowledge of bleeding and thrombotic disorders • Stay current in contemporary issues, products, research, and methodologies • Learn about state-of-the art tests, equipment, ...